Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.
Also called NCT03436693
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 308 participants
- Sponsor
- Registry
-
NCT03436693
-
- Other papers using this trial's data
- Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03436693. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-15 (actual); primary completion 2021-01-21 (actual). Results posted on 2024-07-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tanabe Pharma Corporation
Record details
- Record id
cardio:ct-nct03436693- Content hash
3007168f9a17290f860a77c4eec71c5a4abd582bad3da0c76924a80fe05641a5